MX2020003748A - Vectores adenovirales con dos casetes de expresion que codifican proteinas antigenicas del vsr o fragmentos de las mismas. - Google Patents
Vectores adenovirales con dos casetes de expresion que codifican proteinas antigenicas del vsr o fragmentos de las mismas.Info
- Publication number
- MX2020003748A MX2020003748A MX2020003748A MX2020003748A MX2020003748A MX 2020003748 A MX2020003748 A MX 2020003748A MX 2020003748 A MX2020003748 A MX 2020003748A MX 2020003748 A MX2020003748 A MX 2020003748A MX 2020003748 A MX2020003748 A MX 2020003748A
- Authority
- MX
- Mexico
- Prior art keywords
- fragments
- expression cassettes
- adenoviral vectors
- antigenic proteins
- cassettes encoding
- Prior art date
Links
- 230000000890 antigenic effect Effects 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572951P | 2017-10-16 | 2017-10-16 | |
| PCT/EP2018/078212 WO2019076882A1 (en) | 2017-10-16 | 2018-10-16 | ADENOVIRAL VECTORS COMPRISING TWO EXPRESSION CASSETTES ENCODING RSV ANTIGENIC PROTEINS OR FRAGMENTS THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003748A true MX2020003748A (es) | 2020-11-06 |
Family
ID=63896162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003748A MX2020003748A (es) | 2017-10-16 | 2018-10-16 | Vectores adenovirales con dos casetes de expresion que codifican proteinas antigenicas del vsr o fragmentos de las mismas. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11859199B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3697919A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020537526A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111527213A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020007008A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3079048A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020003748A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019076882A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4177347A4 (en) * | 2020-07-06 | 2024-12-18 | Jiaxing Anyu Biotechnology Co., Ltd | NOVEL CHIMPANZEE ADENOVIRUS VECTOR, PRODUCTION PROCESS AND USE THEREOF |
| WO2022102894A1 (ko) * | 2020-11-10 | 2022-05-19 | 주식회사 바이오리더스 | 코로나바이러스의 스파이크 단백질 및 뉴클레오캡시드 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신 |
| KR102399308B1 (ko) * | 2020-11-10 | 2022-05-20 | 주식회사 비엘 | 코로나바이러스의 스파이크 단백질 및 뉴클레오캡시드 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신 |
| KR102882279B1 (ko) * | 2022-05-09 | 2025-11-10 | 주식회사 모아라이프플러스 | 코로나바이러스의 스파이크 단백질, 뉴클레오캡시드 단백질 및 PgsA 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005015728A1 (de) | 2005-04-06 | 2006-10-12 | Robert Bosch Gmbh | Verbindungsvorrichtung für einen Antrieb sowie Verfahren zur Herstellung einer Verbindungsvorrichtung |
| WO2008095027A2 (en) * | 2007-01-30 | 2008-08-07 | Cedars-Sinai Medical Center | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene |
| EP2181121A4 (en) | 2007-03-21 | 2012-07-11 | Id Biomedical Corp Quebec | CHIMÄRE ANTIGENE |
| EP3385387B1 (en) | 2009-02-02 | 2021-08-25 | GlaxoSmithKline Biologicals SA | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
| WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
| CN103492574B (zh) | 2011-02-22 | 2015-12-09 | 加州理工学院 | 使用腺相关病毒（aav）载体递送蛋白 |
| JP2016503422A (ja) | 2012-11-16 | 2016-02-04 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | プロスタグランジンｅｐ４アゴニストの組み合わせを用いた皮膚創傷の治癒および瘢痕の減少 |
| MX384992B (es) * | 2014-06-13 | 2025-03-14 | Glaxosmithkline Biologicals Sa | Combinaciones inmunógenas. |
| BE1024420B1 (fr) | 2015-06-12 | 2018-02-19 | Glaxosmithkline Biologicals Sa | Polynucleotides et polypeptides d'adenovirus |
| GB201513176D0 (en) | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
-
2018
- 2018-10-16 EP EP18789095.9A patent/EP3697919A1/en not_active Withdrawn
- 2018-10-16 US US16/756,380 patent/US11859199B2/en active Active
- 2018-10-16 BR BR112020007008-4A patent/BR112020007008A2/pt not_active IP Right Cessation
- 2018-10-16 CA CA3079048A patent/CA3079048A1/en not_active Abandoned
- 2018-10-16 CN CN201880081339.5A patent/CN111527213A/zh not_active Withdrawn
- 2018-10-16 JP JP2020521363A patent/JP2020537526A/ja not_active Withdrawn
- 2018-10-16 MX MX2020003748A patent/MX2020003748A/es unknown
- 2018-10-16 WO PCT/EP2018/078212 patent/WO2019076882A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019076882A1 (en) | 2019-04-25 |
| JP2020537526A (ja) | 2020-12-24 |
| CN111527213A (zh) | 2020-08-11 |
| BR112020007008A2 (pt) | 2020-11-17 |
| CA3079048A1 (en) | 2019-04-25 |
| US20210189422A1 (en) | 2021-06-24 |
| EP3697919A1 (en) | 2020-08-26 |
| US11859199B2 (en) | 2024-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003748A (es) | Vectores adenovirales con dos casetes de expresion que codifican proteinas antigenicas del vsr o fragmentos de las mismas. | |
| CY1124213T1 (el) | Διαβιβαστες aav που περιεχουν γονιδιο κωδικοποιησης του παραγοντα viii | |
| UY40283A (es) | Método para alterar una propiedad de una planta | |
| CY1122833T1 (el) | Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7 | |
| UA124343C2 (uk) | Капсиди аденоасоційованого вірусу і спосіб його використання | |
| CY1124921T1 (el) | Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων | |
| CY1124171T1 (el) | Μη ανθρωπινα ζωα με εξανθρωπισμενο γονιδιο ενεργοποιησης λεμφοκυτταρων 3 | |
| CY1122705T1 (el) | Αντιγονα, διαβιβαστες, συνθεσεις του ιου της ανθρωπινης ανοσοανεπαρκειας,και μεθοδοι χρησης τους | |
| MX2019000962A (es) | Novedosas proteinas de la capside del virus adenoasociado. | |
| MX2017004664A (es) | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. | |
| EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
| MX2021000263A (es) | Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma. | |
| MX2016004579A (es) | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| CY1124727T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
| MX2020011529A (es) | Un metodo para optimizar la expresion de anticuerpos. | |
| MX2018012550A (es) | Composiciones y metodos para la deteccion de proteinas de celulas huesped. | |
| PH12020552222A1 (en) | Immunodominant proteins and fragments in multiple sclerosis | |
| WO2020022898A3 (en) | Off-the-shelf cancer vaccines | |
| RU2015102383A (ru) | ЭКСПРЕССИРУЮЩИЕ ПЛАЗМИДНЫЕ ВЕКТОРЫ pET32a(+)ASFV/p30e1 И pET32b(+)ASFV/p30e2 ДЛЯ СИНТЕЗА РЕКОМБИНАНТНЫХ БЕЛКОВ, СОСТОЯЩИХ ИЗ ФРАГМЕНТА p30 ВИРУСА АФРИКАНСКОЙ ЧУМЫ СВИНЕЙ, ТИОРЕДОКСИНА И ПОЛИГИСТИДИНОВЫХ УЧАСТКОВ | |
| WO2020068196A3 (en) | Proteins that inhibit cas12a (cpf1), a crispr-cas nuclease | |
| EP4085064A4 (en) | LOOP PROTEINS INCLUDING CELL-PENETRATING PEPTIDES | |
| EP3994160A4 (en) | MODIFIED BCL9 MIMETIC PEPTIDES | |
| PE20200487A1 (es) | Proteinas de union al antigeno anti-jagged1 | |
| EA201790241A1 (ru) | Эффективная селективность в отношении рекомбинантных белков |